Advanced Sterilization Products (ASP), part of the Johnson & Johnson Medical Devices Companies, announced the new STERRAD 100NX System with ALLClear Technology is now available in the United States and to select customers in Europe, Middle East and Africa (EMEA). Recently cleared by the U.S. Food and Drug Administration (FDA), the next-generation system is designed to help Central Sterile Services Departments (CSSDs) maximize efficiency and comply with government and facility requirements.
CSSDs frequently handle thousands of instruments a day, working under pressure to ensure each one is clean, sterile, and properly functioning. Any issues or delays during the sterilization process can cause disruption to operating room schedules and put patients in danger of healthcare-associated infections.
The new STERRAD 100NX System with ALLClear Technology is a low-temperature sterilization system that uses proprietary algorithms to minimize workflow interruptions and cycle cancellations. The system includes features that simplify system operation and automatically monitors conditions, providing pre-sterilization cycle load conditioning, load checks, and system checks to reduce operator error while improving productivity.
“We developed the new STERRAD 100NX System with ALLClear Technology to help CSSDs deliver instruments to operating rooms faster and more consistently, providing doctors and patients with the devices they need, when they need them,” says Suneel Shorey, Vice President of ASP Global Marketing. “This new system is the first in a series of innovations we plan to introduce globally in 2017 to help elevate the standard of care in sterilization and build on our heritage as a leader in infection prevention.”
Additionally, the STERRAD 100NX System with ALLClear Technology can be paired with ASP ACCESS to automate data sharing across all connected ASP systems and hospital networks, minimizing the need for manual documentation. Systems are currently in use at a select number of hospitals in the United States and Europe. It will be rolled out in Australia, New Zealand, Canada, Latin America, and Japan, as well as additional markets in EMEA and Asia Pacific, throughout 2017.